Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
Technology
Health & Fitness
About Us
Contact Us
Copyright
© 2024 PodJoint
Podjoint Logo
US
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/e8/c7/b5/e8c7b528-17b1-e0a9-427d-622bcbb740e8/mza_3250078780769455117.jpg/600x600bb.jpg
CReATe Podcast
CReATe Consortium
79 episodes
2 weeks ago
CReATe Connect podcasts are short recorded interviews on topics we hope will be of interest to patients with ALS and other motor neuron diseases.
Show more...
Health & Fitness
RSS
All content for CReATe Podcast is the property of CReATe Consortium and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
CReATe Connect podcasts are short recorded interviews on topics we hope will be of interest to patients with ALS and other motor neuron diseases.
Show more...
Health & Fitness
https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/304f436c9370c5ce5056406549ff413e.jpg
CReATe Author Series Ep. 14 - Drs. Ruben van Eijk and Michael Benatar on Phase 2 Trials and ALS
CReATe Podcast
36 minutes
6 months ago
CReATe Author Series Ep. 14 - Drs. Ruben van Eijk and Michael Benatar on Phase 2 Trials and ALS
Dr. Ruben van Eijk is an associate professor in the Department of Neurology at the University Medical Center Utrecht in the Netherlands as well as a statistical consultant and medical statistician for the clinical trial methodology group at the Julius Center also in Utrecht.  Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami.  They will be discussing their recent publication “Rethinking phase 2 trials in amyotrophic lateral sclerosis”.
CReATe Podcast
CReATe Connect podcasts are short recorded interviews on topics we hope will be of interest to patients with ALS and other motor neuron diseases.